RCC Drug Pipeline: HIF-2α, IO & VEGFR — PatSnap Eureka
Renal Cell Carcinoma Pipeline: HIF-2α Inhibitors, IO Combinations & VEGFR Strategies
Clear cell RCC — representing approximately 70–85% of kidney cancer cases — is driven by VHL loss and HIF pathway activation. Explore patent and literature signals across three major therapeutic axes shaping the next generation of RCC treatment.
VHL Loss Drives the Central Oncogenic Pathway in ccRCC
Renal cell carcinoma is the most common form of kidney cancer, with clear cell RCC (ccRCC) representing approximately 70–85% of cases. The disease remains a challenging therapeutic target due to its resistance to conventional chemotherapy and its complex molecular biology. Loss of the VHL tumor suppressor — present in the majority of ccRCC tumors — leads to constitutive activation of hypoxia-inducible factors, promoting angiogenesis via VEGF upregulation, metabolic reprogramming via GLUT1/SLC2A1, and immune evasion.
The patent landscape analysis across retrieved records consistently identifies the VEGF/VEGFR signaling axis as the most extensively covered target cluster. Multiple patents from Exelixis, Acceleron Pharma, and Genentech/Roche center on VEGFR inhibition and VEGF antagonism as primary or combinatorial strategies. Biomarker genes including VEGFA, KDR (VEGFR2), FLT1 (VEGFR1), ESM1, PECAM1, ANGPTL4, and CD34 are cited as predictive signatures for VEGF-directed therapy response.
Beyond the VEGF axis, HIG2 (hypoxia-inducible protein 2) is identified as overexpressed in ccRCC relative to normal renal tissue, with ELISA analyses confirming plasma secretion of HIG2 protein in RCC patients even at early tumor stages. MET and AXL upregulation — a consequence of VHL protein loss — provides the mechanistic rationale for multi-kinase targeting approaches. According to published literature, approximately 24.5% of RCC tumors are TP53-positive, defining a biomarker-selected population for MDM2-p53 combination strategies.
RCC Pipeline: Key Data Visualisations
Derived from patent and literature records retrieved across targeted searches. Represents innovation signals within this dataset only.
Seven Distinct Therapeutic Axes in the RCC Drug Pipeline
Patent and literature signals reveal a multi-modal pipeline spanning small molecules, biologics, ADCs, RNA therapeutics, and cell therapy approaches.
Cabozantinib — Dominant Multi-Jurisdictional IP Position
Exelixis holds a family of patents across multiple jurisdictions (US, WO, CA, EP, CN) covering the method of treating advanced RCC in patients who have received prior anti-angiogenic therapy using cabozantinib, an inhibitor of MET, VEGFR2, and AXL. VHL protein loss upregulates both MET and AXL, creating the mechanistic rationale for cabozantinib's broad kinase inhibition profile. This patent cluster represents the most extensively territorialized IP position in this dataset.
ClinicalVEGF Antagonist + PD-L1 Axis Binding Antagonist Combinations
Genentech (Roche) filings cover the combination of VEGF antagonists (bevacizumab, or VEGFR TKIs such as sunitinib, axitinib, pazopanib, or cabozantinib) with PD-L1 axis binding antagonists (atezolizumab or anti-PD-1 antibodies). These filings are positioned around biomarker-guided patient stratification, with particular attention to sarcomatoid RCC as a subtype with possible enhanced benefit. Predictive biomarker genes cited include VEGFA, KDR, ESM1, PECAM1, FLT1, ANGPTL4, and CD34.
ClinicalHIG2 — Plasma-Detectable RCC-Selective Target
Oncotherapy Science patents describe methods of inhibiting RCC cell growth via HIG2 siRNA or HIG2 antibody contact with cancer cells. HIG2 (hypoxia-inducible protein 2) is overexpressed in ccRCC and detectable in patient plasma by ELISA at early tumor stages. siRNA knockdown and antibody-mediated targeting of HIG2 suppress RCC cell proliferation in vitro. The hypoxia-responsive transcriptional regulation of HIG2 links this target directly to the VHL–HIF axis.
PreclinicalAnti-CDH6 ADC + HIF-2α Inhibitor — Most Novel Signal in Dataset
A 2026 Daiichi Sankyo patent (EP and CA) describes a combination of a specific anti-CDH6 antibody-drug conjugate (ADC, drug-linker bound via thioether bond) with an HIF-2α inhibitor for the treatment of renal cell carcinoma, renal clear cell carcinoma, and papillary renal cell carcinoma. This is the only retrieved record explicitly naming HIF-2α inhibitor as a combinatorial partner in an RCC regimen. CDH6 (cadherin-6) is expressed on RCC cells, providing tumor-selective ADC delivery; HIF-2α inhibitor addresses the underlying VHL-loss oncogenic driver.
Early IND-EnablingALK1 ECD Polypeptides — Combination Enhancer for VEGFR TKIs
Acceleron Pharma holds a broad patent family (WO, US, EP, AU, CA, MX, JP, BR) on ALK1 ECD polypeptides and antibodies directed to ALK1 and its ligands (BMP9 and BMP10) for RCC treatment. Retrieved records note that ALK1 ECD polypeptides "dramatically increase" the ability of standard-of-care VEGFR TKIs (sunitinib, sorafenib, pazopanib, axitinib, tivozanib, vandetanib) to inhibit RCC tumor growth in vivo, positioning this modality as a combination enhancer for existing VEGFR-targeted therapy.
Preclinical / In VivoPD-1/PD-L1 Inhibition — Monotherapy and MDM2-p53 Combinations
Multiple patents address PD-1/PD-L1 checkpoint inhibition in RCC. Novartis filings specifically target TP53 wild-type RCC with anti-PD-1 antibody + HDM2-p53 interaction inhibitor combinations, citing a nivolumab median OS of 25 months vs. 19.6 months for everolimus in previously treated RCC patients. Genentech's "classifying and treating kidney cancer" filings (2023–2024) instruct atezolizumab + bevacizumab regimens guided by mRNA-based tumor classification in previously untreated locally advanced or metastatic RCC.
Clinical Signals PresentSix Combination Strategies Shaping the Next RCC Pipeline
Retrieved results signal convergence toward dual-mechanism and biomarker-stratified combination approaches across all major therapeutic axes.
ADC + HIF-2α Inhibitor (anti-CDH6 ADC)
The most novel combination signal in this dataset, from two pending Daiichi Sankyo filings (EP and CA, 2025–2026). CDH6-directed ADC delivers cytotoxic payload to tumor cells; HIF-2α inhibitor addresses the underlying VHL-loss oncogenic driver. This orthogonal combination — ADC-mediated payload delivery plus transcription factor inhibition — represents an emergent dual-mechanism approach for ccRCC and papillary RCC.
VEGFR TKI + ALK1 ECD Polypeptide
Acceleron filings signal a rationale for combining ALK1 ECD antagonism with standard-of-care VEGFR TKIs, with preclinical data showing dramatic enhancement of TKI efficacy in vivo. The ALK1/BMP9/BMP10 signaling node on activated tumor endothelial cells provides multi-factor anti-angiogenic activity distinct from direct VEGF/VEGFR blockade, and combination with sunitinib, sorafenib, pazopanib, and other VEGFR TKIs is described in retrieved records.
PD-1/PD-L1 + VEGFR TKI Stratified by TME Type
Genentech/Boston Gene filings signal a trend toward molecular TME subtyping to optimize IO + VEGFR combination assignment. The RC TME type methodology (Boston Gene, 2024 JP pending) proposes that immunotherapy-responsive vs. TKI-responsive ccRCC subtypes can be distinguished by gene expression profiling. Genentech's biomarker signatures (VEGFA, KDR, ESM1) serve a similar patient-selection function across multiple jurisdictions.
PD-1 + MDM2-p53 Inhibitor in TP53 Wild-Type RCC
Novartis filings (MX, CA, ES) signal an emerging IO combination exploiting p53 pathway restoration as a complementary mechanism to checkpoint release, specifically in the TP53-intact RCC population. Approximately 24.5% TP53 positivity in RCC (cited from a 2,519-tumor meta-analysis) limits applicability but defines a biomarker-selected patient population for this strategy.
Major Patent Assignees in the RCC Drug Pipeline
Activity is divided between large pharmaceutical companies (predominantly patent-driven) and academic institutions. The IP analytics platform reveals multi-jurisdictional coverage patterns across all major assignees.
| Assignee | Therapeutic Focus | Jurisdictions | Stage Signal | Key Targets |
|---|---|---|---|---|
| Genentech / Roche | IO-VEGFR combinations; biomarker-guided therapy; sarcomatoid RCC classification | JP, CN, TW, WO, MX, US, CA | Clinical | VEGFA, KDR, ESM1, PD-L1, VEGFR TKIs |
| Exelixis, Inc. | Cabozantinib method-of-use in prior anti-angiogenic therapy RCC | WO, US (multiple), CA, EP, CN | Clinical | MET, VEGFR2, AXL |
| Acceleron Pharma | ALK1 ECD polypeptides; multi-factor angiogenesis inhibition | WO, US, EP, AU, CA, MX, JP, BR | Preclinical / In Vivo | ALK1, BMP9, BMP10, VEGFR TKIs |
| Oncotherapy Science | HIG2 siRNA and antibody targeting; RCC gene expression diagnostics | WO, EP, JP, CN | Preclinical | HIG2 (HIGU), VHL–HIF axis |
| Daiichi Sankyo | Anti-CDH6 ADC + HIF-2α inhibitor combination | EP, CA (pending) | Early IND-Enabling | CDH6, HIF-2α (EPAS1) |
| Novartis AG | PD-1 antibody + HDM2-p53 inhibitor in TP53 wild-type RCC | MX, CA, ES | Clinical Signals | TP53, MDM2, PD-1 |
Track RCC Assignee IP Movements in Real Time
Monitor new filings, jurisdiction expansions, and expiry signals across all major RCC patent holders
Key Clinical Evidence Referenced Across RCC Patent Filings
Retrieved results contain several clinically significant signals. Exelixis patent filings directly reference clinical use in human patients who have received prior anti-angiogenic therapy, citing clinical comparators including nivolumab versus everolimus and referencing MET/VEGFR2/AXL inhibition as the mechanistic basis for clinical activity. A life sciences IP analysis of these filings reveals multi-jurisdictional method-of-use claims.
A Novartis patent filing cites a nivolumab median OS of 25 months vs. 19.6 months for everolimus in previously treated RCC patients (citing Mazza et al., 2017), along with reference to the approved nivolumab label for RCC. A University of Michigan WO patent (2024) cites KEYNOTE-426 phase 3 trial data (Powles et al., Lancet Oncol 2020) confirming pembrolizumab + axitinib as a validated first-line standard.
An Eisai R&D Management patent identifies IL-18BP, ICAM-1, FGF-21, and M-CSF as pre-treatment biomarker predictors of response to lenvatinib + everolimus combination in RCC patients, indicating this combination is in active clinical development with companion diagnostic efforts. The PatSnap customer community includes R&D teams actively tracking these biomarker companion diagnostic developments. No retrieved records contain direct reports of phase 3 trial outcomes for HIG2 inhibitors, ALK1 ECD polypeptides, or the Daiichi Sankyo anti-CDH6 ADC + HIF-2α inhibitor combination.
IP Strategy Signals Across the RCC Pipeline
Patent lifecycle analysis reveals where competitive battlegrounds are forming and where freedom-to-operate windows may exist.
Renal Cell Carcinoma Drug Pipeline — key questions answered
The VEGF/VEGFR signaling axis is the most extensively covered target cluster in retrieved results. Multiple patents from Exelixis, Acceleron Pharma, and Genentech/Roche center on VEGFR inhibition and VEGF antagonism as primary or combinatorial strategies. Biomarker genes including VEGFA, KDR (VEGFR2), FLT1 (VEGFR1), ESM1, PECAM1, ANGPTL4, and CD34 are cited as predictive signatures for VEGF-directed therapy response.
Cabozantinib (brand name CABOMETYX) is a multi-targeted receptor tyrosine kinase inhibitor (RTKI) that inhibits MET, VEGFR2, and AXL. Exelixis holds a family of patents across multiple jurisdictions (US, WO, CA, EP, CN) covering the method of treating advanced RCC in patients who have received prior anti-angiogenic therapy using cabozantinib. This patent cluster represents the most extensively territorialized IP position in this dataset.
A strategically significant recent patent from Daiichi Sankyo (2026, EP and CA) describes a combination of a specific anti-CDH6 antibody-drug conjugate (ADC) with an HIF-2α inhibitor for the treatment of renal cell carcinoma, renal clear cell carcinoma, and papillary renal cell carcinoma. This is the only retrieved record explicitly naming HIF-2α inhibitor as a combinatorial partner in an RCC regimen, representing a next-generation combination approach bridging ADC and HIF-pathway modalities.
HIG2 (hypoxia-inducible protein 2) is identified across multiple Oncotherapy Science and Katagiri Toyomasa patents as a plasma-secretable RCC-selective protein detectable by ELISA in early-stage RCC patients. siRNA knockdown and antibody-mediated targeting of HIG2 suppress RCC cell proliferation in vitro. The hypoxia-responsive transcriptional regulation of HIG2 links this target directly to the VHL–HIF axis, and its utility as both a diagnostic marker and therapeutic target is proposed.
Genentech/Roche holds the most extensive patent positions linking TME gene expression signatures (VEGFA, KDR, ESM1, FLT1, ANGPTL4, CD34) to VEGF antagonist + PD-L1 axis binding antagonist combination therapy outcomes in RCC. The RC TME type methodology (Boston Gene, 2024 JP pending) proposes that immunotherapy-responsive vs. TKI-responsive ccRCC subtypes can be distinguished by gene expression profiling. Sarcomatoid RCC is specifically identified as a biomarker-selected subpopulation likely to benefit.
Retrieved signals for siRNA, miRNA, and CD70-directed cell therapy in RCC are at preclinical stages and represent white space for organizations with RNA delivery or cell therapy platforms. A 2025 pending JP patent describes TCR-like fusion molecules targeting CD70 for RCC. Two retrieved records describe RNA-based therapeutic approaches: a 2025 Chinese patent claiming siRNA sequences delivered via self-assembling in vivo RNA delivery systems, and a Japanese patent covering miRNA carriers delivered via extracellular vesicles derived from mesenchymal stem cells.
Still have questions about the RCC drug pipeline? Let PatSnap Eureka answer them for you.
Ask Eureka About RCC PatentsAccelerate Your RCC Drug Pipeline Research
Join 18,000+ innovators already using PatSnap Eureka to accelerate their R&D. Map HIF-2α combination IP, track IO-VEGFR assignee movements, and identify white space in the RCC patent landscape.
References
- [1] Diagnostic and therapeutic methods for sarcomatoid kidney cancer — Genentech, Inc., 2025, JP [Patent]
- [2] Diagnostic and therapeutic methods for cancer — Genentech, Inc., 2020, JP [Patent]
- [3] Hypoxia-inducible protein 2 (HIG2), a novel therapeutic potential target of renal cell carcinoma (RCC) — Katagiri, Toyomasa, 2005, WO [Patent]
- [4] Hypoxia-inducible protein 2 (HIG2), a novel therapeutic potential target of renal cell carcinoma (RCC) — Oncotherapy Science, Inc., 2006, EP [Patent]
- [5] Combination of Anti-CDH6 antibody-drug conjugate and HIF-2alpha inhibitor — Daiichi Sankyo Company, 2026, EP [Patent]
- [6] Method of Treating Renal Cell Carcinoma Using Cabozantinib — Exelixis, Inc., 2022, US [Patent]
- [7] ALK1 antagonists and their uses in treating renal cell carcinoma — Acceleron Pharma Inc., 2013, WO [Patent]
- [8] Pharmaceutical combinations (PD-1 + HDM2-p53 inhibitor) — Novartis AG, 2019, CA [Patent]
- [9] Application of UGDH in diagnosis, treatment, and prognosis prediction of renal cancer — Peking University First Hospital, 2025, CN [Patent]
- [10] Cell surface molecules as markers and therapeutic agents against kidney cancers — Howes, Steven, 2005, WO [Patent]
- [11] Method of treating renal cell carcinoma using cabozantinib — Exelixis, Inc., 2017, CA [Patent]
- [12] Method of treating renal cell carcinoma using cabozantinib — Exelixis, Inc., 2019, EP [Patent]
- [13] Diagnostic and therapeutic methods for sarcomatoid kidney cancer — Genentech, Inc., 2021, MX [Patent]
- [14] Methods and compositions for classifying and treating kidney cancer — Genentech, Inc., 2024, US [Patent]
- [15] HIG2 as a potential novel therapeutic target for RCC — Oncotherapy Science, Inc., 2011, JP [Patent]
- [16] Combination of Anti-CDH6 antibody-drug conjugate and HIF-2α inhibitor — Daiichi Sankyo Company, 2026, CA [Patent]
- Powles et al. Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma (KEYNOTE-426) — Lancet Oncology, 2020
- National Cancer Institute — Renal Cell Cancer Treatment (PDQ) — cancer.gov
- Mazza et al. Nivolumab in previously treated advanced renal-cell carcinoma — PubMed / NCBI, 2017
All data and statistics on this page are sourced from the references above and from PatSnap's proprietary innovation intelligence platform. Patent records retrieved via PatSnap Eureka. This report represents a snapshot of innovation signals within the retrieved dataset only and should not be interpreted as a comprehensive view of the full field, clinical pipeline, or regulatory landscape.
PatSnap Eureka searches patents and research to answer instantly.